Is MS an inflammatory or primary degenerative disease?

Area of Science:

• Neuroimmunology
• Neurology
• Pathophysiology of Multiple Sclerosis

Background:

• Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
• Neuroinflammation in MS involves a complex interplay of molecular and cellular components, including T cells, B cells, microglia, and macrophages.
• Inflammation, demyelination, and neurodegeneration are key pathological hallmarks of MS, present across its various forms.

Purpose of the Study:

• To elucidate the multifaceted role of neuroinflammation in the pathogenesis of multiple sclerosis.
• To examine the contribution of various immune cells and molecules to MS pathology.
• To evaluate the efficacy of current anti-inflammatory and immunomodulatory therapies in different stages of MS.

Main Methods:

• Review of molecular and cellular mechanisms underlying neuroinflammation in MS.
• Analysis of the involvement of immune cells (CD4+ T cells, CD8+ T cells, B cells, microglia, macrophages) in MS pathogenesis.
• Assessment of the impact of inflammation on myelin sheath and axonal integrity.
• Evaluation of the effectiveness of anti-inflammatory and immunomodulatory treatments in different MS disease courses.

Main Results:

• Neuroinflammation in MS is mediated by cytokines, chemokines, adhesion molecules, and immune cells.
• CD4+ T cells, CD8+ T cells, and B cells play critical roles in driving inflammation and direct tissue damage.
• While anti-inflammatory therapies are effective in relapsing-remitting MS, their efficacy diminishes in progressive forms due to the blood-brain barrier.
• Inflammation can persist in progressive MS, but may be less accessible to current treatments.

Conclusions:

• Neuroinflammation is a central feature of multiple sclerosis, contributing to demyelination and neurodegeneration.
• The effectiveness of immunomodulatory therapies is stage-dependent, highlighting the need for novel therapeutic strategies for progressive MS.
• Understanding the dynamics of neuroinflammation and the blood-brain barrier is crucial for developing more effective treatments for all MS patients.